Analysis of the relationship between Erdafitinib and BOC

Erdafitinib and Balversa are different trade names for the same drug. The former is the generic name of the drug, while the latter is its trade name in the Chinese market. Therefore, both refer to the exact same drug, just with different brand names for different markets.

Balversa (Balversa), the trade name of erdafitinib in China, is a targeted drug developed and approved by Incyte Corporation. Boco's approval in China is to meet the treatment needs of patients with advanced urothelial cancer (bladder cancer), especially those carrying FGFR gene mutations or amplifications. The drug effectively slows down the growth and spread of tumors by inhibiting the fibroblast growth factor receptor (FGFR) signaling pathway.

As a molecular targeted drug, the main mechanism of action of Erdafitinib is to selectively inhibit the activity of receptors such asFGFR1, FGFR2, and FGFR3, thereby blocking the tumor growth signals triggered by these receptors. Since these FGFR pathways play an important role in the occurrence and development of various cancers, erdafitinib can effectively combat cancers related to these gene mutations, especially in the treatment of refractory cancers such as urothelial cancer.

In summary, there is no actual difference between erdafitinib and BOC, they only differ in their market and brand names. In China, patients can obtain treatment with the drug under the brand name Boco, while in other countries or regions, erdafitinib is widely used as the international generic name. For patients, both erdafitinib and BOC are important treatment options that can provide highly targeted targeted therapy and effectively improve the survival and quality of life of patients with advanced urothelial cancer.

References：https://www.balversa.com/